Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242339 (
dyslipidemia
)
13,927
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tinnitus
can cause extreme morbidity. Despite many attempts to find a treatment for idiopathic cases, they remain difficult to manage. Because nerve injury is one of the suspected etiologies of
tinnitus
and because gabapentin has been found to be effective in treating nerve injuries, some authors have attempted to determine if gabapentin has a role in treating
tinnitus
. Although gabapentin was found to be ineffective for
tinnitus
in these previous studies, to the best of our knowledge no studies have been performed that took into consideration the presence of various accompanying factors and concomitant diseases that might influence its effect. We conducted a prospective, randomized, double-blind, placebo-controlled clinical trial of gabapentin for idiopathic
tinnitus
. We treated 40 patients with gabapentin and measured its effectiveness by comparing differences between pre- and post-treatment
Tinnitus
Severity Index (TSI) values and
tinnitus
loudness scores. We also compared these outcomes with those of a group of 40 matched placebo controls. At study's end, we found no significant differences between the gabapentin and control groups in mean decreases in TSI value and loudness score (p=0.85 and p=0.12, respectively). However, we did find that patients with hypertension, diabetes, and/or
dyslipidemia
showed a better response to gabapentin than did those with
tinnitus
alone (p=0.01). We conclude that although there was no statistically significant difference between gabapentin and placebo in treating isolated
tinnitus
or
tinnitus
overall, patients with concomitant hypertension, diabetes, and/or
dyslipidemia
may benefit from gabapentin.
...
PMID:Efficacy of gabapentin on subjective idiopathic tinnitus: a randomized, double-blind, placebo-controlled trial. 2150 Jan 66